Bispecific SIRPα-VEGFR1 Fusion Protein

Anti-CD80 monoclonal antibody (66,406-1-Ig, Proteintech), anti-CD163 monoclonal antibody (GB13340, Servicebio), anti-CD8 monoclonal antibody (GB12068, Servicebio), anti-CD31 monoclonal antibody (GB113151, Servicebio), VEGFA Monoclonal antibody (19,003-1-AP, Proteintech), anti-CD47 monoclonal antibody (ab218810, Abcam), carboxyfluorescein diacetate succinimidyl ester (CFDA SE) (C0051, Beyotime), PerCP anti-CD68 (333,813, BioLegend), PE anti-CD11b (101,208, BioLegend), granulocyte–macrophage colony-stimulating factor (GM-CSF) (C003, novoprotein), FITC-labeled anti-CD47 (CC2C6, BioLegend), Human Lymphocyte separation medium (7,111,011, DAKEWE). The fusion protein SIRPα-Fc has been engineered based on the initial extracellular domain of SIRPα and is currently undergoing Phase I/II clinical trial (NCT05140811) [32 (link)]. SIRPα-VEGFR1 is constructed by combining the extracellular domain of SIRPα with that of VEGFR1 (GenBank accession number: MG920788).

Free full text: Click here

Zhang K., Xu Y., Chang X., Xu C., Xue W., Ding D., Nie M., Cai H., Xu J., Zhan L., Han J., Cai T., Ju D., Feng L., Zhang X, & Yin K. (2024). Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer. Cancer Immunology, Immunotherapy : CII, 73(4), 75.

Publication 2024

GB13340 GB12068 GB113151 VEGFA ab218810 CFDA SE PE anti-CD11b Human Lymphocyte separation medium

Corresponding Organization : Minhang District Central Hospital

Other organizations : Changhai Hospital, Second Military Medical University

Top 5 similar protocols

Variable analysis

independent variables

Anti-CD80 monoclonal antibody (66,406-1-Ig, Proteintech)
Anti-CD163 monoclonal antibody (GB13340, Servicebio)
Anti-CD8 monoclonal antibody (GB12068, Servicebio)
Anti-CD31 monoclonal antibody (GB113151, Servicebio)
VEGFA Monoclonal antibody (19,003-1-AP, Proteintech)
Anti-CD47 monoclonal antibody (ab218810, Abcam)
Carboxyfluorescein diacetate succinimidyl ester (CFDA SE) (C0051, Beyotime)
PerCP anti-CD68 (333,813, BioLegend)
PE anti-CD11b (101,208, BioLegend)
Granulocyte–macrophage colony-stimulating factor (GM-CSF) (C003, novoprotein)
FITC-labeled anti-CD47 (CC2C6, BioLegend)
Human Lymphocyte separation medium (7,111,011, DAKEWE)
SIRPα-Fc
SIRPα-VEGFR1

dependent variables

Not explicitly mentioned

control variables

Not explicitly mentioned

controls

No positive or negative controls were explicitly mentioned in the provided information.

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!